ArticleHeliyon2022
Clinical management of myoid hamartomas of the breast: A case report and literature review.
Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Uncommon but Important: Tertiary Center Experience with Rare Cases of Breast Hamartoma.Life (Basel, Switzerland) · 2025Article
- A rare case of mammary hamartoma presenting as malignant on radiological assessment and benign on pathological examination: a case report.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myoid Hamartoma of the breast (MHB) is an extremely rare benign breast lesion composed of mammary ducts and lobules, fibrous stroma, adipose tissue, and smooth muscle. Due to its rarity, the clinical management of MHB is not well described. Surgical excision is the most common form of management. This study reviews the current literature on the clinical management of MHB and describes a case report of a young patient presenting with MHB managed with surveillance and shared-decision making. Materials and methods: A healthy 23-year-old female presented with a one-year history of a palpable left breast mass. Her right breast exam was normal. Ultrasound of the left breast revealed a 2.7 cm × 1.4 cm × 2.4 cm lobulated mass at the one o'clock position. The mass caused slight discomfort to palpation but otherwise had no associated skin changes. Ultrasound-guided biopsy revealed a left breast myoid hamartoma. Management options were presented to the patient, and she elected to observe the mass with surveillance imaging. Results: There have been no reported cases in the literature of malignant transformation of MHB. Rather than rely on reflexive surgical excision of MHB, our review suggests that surveillance and routine imaging may be an appropriate form of clinical management in patients who present with a favorable clinical and histopathological profile which includes: a low MIB-1 proliferative index, low breast cancer risk assessment score, lesion size less than 1.2 cm, and radiological-pathological concordance. Conclusion: Further research is needed to determine the clinical significance and threshold levels of these clinical and histopathological factors in patient care. However, given current trends to minimize over treatment in breast pathology, we pose that observation of MHB can be performed when favorable clinical criteria is met.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.